Built to Transform
Cancer Care

What began as a vision from a small team of engineers has evolved into a global cancer AI ecosystem. At Lunit, we're redefining how cancer is detected, treated, and understood.

Lunit is transforming cancer diagnosis and treatment through a platform-based approach. Our modular AI ecosystem connects imaging, pathology, and biomarker insights across the entire care pathway—delivering meaningful impact in real-world settings.

With a global presence, we partner with healthcare and biopharma leaders to bring clinically proven solutions that advance precision care and improve performance at scale.

Mission

Conquering cancer together through the power of AI: From screening to research and development, Lunit is transforming how the world detects and develops cancer biomarkers – boldly, intelligently, and with humanity at the core.

Vision

We aim to transform the future of cancer care by making precision AI a trusted partner across the full cancer continuum – empowering earlier detection, advanced biomarker development, and better outcomes for every patient, everywhere.

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

Signed partnership agreement with Microsoft
Officially launched Lunit INSIGHT CXR4 and received CE mark under EU MDR
Signed partnership agreement with the U.S. National Cancer Institute

Surpassed 10,000 medical institutions worldwide adopting Lunit AI

Signed partnership agreement with AstraZeneca
Completed acquisition of Volpara

Joined the World Economic Forum as an Associate Partner—the first medical AI company to advance from Technology Pioneer status
Launched 3D breast screening product Lunit INSIGHT DBT and received CE mark under EU MDR
Launched the Guardant360 TissueNext PD-L1 test powered by Lunit SCOPE PD-L1

First showcased biomarker products Lunit SCOPE IO and Lunit SCOPE PD-L1
Received CE mark for Lunit SCOPE PD-L1
Completed Initial Public Offering on KOSDAQ

Recommended by the World Health Organization (WHO) as a diagnostic tool to replace medical professionals in tuberculosis screenings
Secured $26M Series C-Tranche B funding from Guardant Health
Raised $61M in Pre-IPO round led by HealthQuest and Naver

Received PMDA approval for CXR-AID, developed in collaboration with Fujifilm (Japan)
Received FDA clearance for Lunit INSIGHT MMG
Received FDA clearance for Lunit INSIGHT CXR Triage

First showcased Lunit INSIGHT Chest CT and Lunit INSIGHT DBT
Named to Digital Health 150 by CB Insights
Signed partnership agreements with Philips, Guardant Health, and Agfa

Signed partnership agreement with GE Healthcare
Secured $27M Series C-Tranche A funding led by Shinhan Investment
Received CE mark for Lunit INSIGHT MMG

Named a “Technology Pioneer 2020” by the World Economic Forum
Named to Digital Health 150 by CB Insights

Named to Digital Health 150 by CB Insights
Received clearance from Korea’s Ministry of Food and Drug Safety for Lunit INSIGHT MMG
Received CE mark for Lunit INSIGHT CXR

Won 1st place in Visual Domain Adaptation Challenge
Secured $5M Series B1 funding led by Fujifilm

Secured $15M Series B funding led by Intervest
Received clearance from Korea’s Ministry of Food and Drug Safety for Lunit INSIGHT CXR-Nodule
Launched breast screening product Lunit INSIGHT MMG

Signed partnership agreement with Fujifilm

Named among Top 100 AI Startup by CB Insights
Recognized as a Top 5 “Social Impact” AI Startup by NVIDIA
Won 1st place in CAMELYON Grand Challenge 2017

Placed 5th in the Digital Mammography DREAM Challenge
Launched first chest X-ray product, Lunit INSIGHT CXR-Nodule

Secured $3.3M Series A1 funding led by SoftBank Ventures Asia
Won 1st place in MICCAI Tumor Proliferation Assessment Challenge

Placed 5th in ImageNet Challenge
Secured $2M Series A funding led by SoftBank Ventures Asia

Pivoted to medical imaging and rebranded as Lunit
Secured $0.1M seed funding from Kakao Ventures

Company founded (as CLDI)

Our Partners

From diagnostics to oncology, we collaborate with world-class healthcare providers, life science companies, and technology leaders—united by a shared mission to redefine how the world fights cancer with AI.